Overexpression of PD-L1 in tumour cells leads to the escape of inhibitory pathways from host immune surveillance (3, 4), thus providing a scientific basis for the use of immune checkpoint inhibitors (ICIs) in cancer. The gene discussed is CD274; the disease is neoplasm.